The effect of Etlingera elatior J. flower on the pulmo histology of white rat (Rattus novergicus L.) after cigarette smoke exposure

Cigarette smoking is one of health issues that mainly harmed the lung due to its free radicals. Kecombrang (Etlingera elatior J.) is a medicinal plant known to have a high amount of antioxidant. This study aims to determine the effect of antioxidant in Etlingera elatior J. flower on the improvement of pulmonary histology of male white rats (Rattus novergicus L.) as the secondhand smoke (cigarette exposure). This research was conducted by experimental method with ethanol extract of Etlingera elatior J. flower and pulmonary organ of white male rats as the test materials. There were 25 white male rats that divided into 5 groups (Positive Control, Negative Control, P1: 30 mg/Kg, P2:60 mg/Kg, and P3:90 mg/Kg). The results were statistically analyzed using One Way ANOVA test and Duncan’s test. The results showed a decreased amount of damage at P1, P2 and P3 groups. The statistical analysis showed that Etlingera elatior J. flower extract had a significant effect (p <0.05) on the histological improvement in each group. Group P2 shows the lowest rate of damage that it can be concluded the most effective dose in repairing the damage to rat pulmonary histology due to exposure of cigarette smoke.

Lupeol Stearate Accelerates Healing and Prevents Recurrence of Gastric Ulcer in Rodents

The gastric healing and gastric ulcer recurrence preventive effect of Lupeol Stearate (LS) was measured in this study. To evaluate the gastric healing effect, rats were submitted to the 80% acetic acid-induced ulcer model and treated with vehicle (1 ml/kg, p.o.), LS (1 mg/kg, p.o.) or omeprazole (20 mg/kg, p.o.) twice a day for seven days. The gastric injury was evaluated macroscopically, histologically and histochemical; and biochemical parameters were also quantified. To evaluate the effects of LS on gastric ulcer recurrence, mice were ulcerated by gastric instillation of 10% acetic acid and treated with vehicle (1 ml/kg, p.o.), LS (1 mg/kg, p.o.) or ranitidine (20 mg/kg, p.o.) twice a day for ten days. Then, the ulcer recurrence in these animals was induced by IL- 1β (1 µg/kg i.p) at five day after the end of the treatment period. The area of the lesion recurred were measured, as well as the activity of myeloperoxidase and TNF levels. Oral treatment with LS accelerated gastric healing by 63% compared to the group treated with vehicle, which was also evidenced by histological improvement and increased production of mucin in the gastric epithelium. LS elevated the activity of the glutathione S-transferase and reduced the activity of myeloperoxidase, but did not change the levels of reduced glutathione or the activity of superoxide dismutase and catalase at the ulcer site in rats. Regarding the recurrence, the LS treatment reduced the recurred lesions, reducing MPO activity but not TNF levels at ulcer site. It can be concluded that LS promotes the healing of gastric lesions by favoring the mucus production and reducing the migration of neutrophils and that it can reduce the severity of the ulcer recurrence.

Influence of barley, corn and rice flour on physical, chemical and sensory characteristics of gluten-free bread

People suffering from the celiac disease have to apply a strict gluten-free diet because this is the only effective management. Nowadays, the increasing incidence of celiac disease promotes worldwide interests for various desirable gluten free products. As a consequence, food processing researchers have been seeking to develop high-quality gluten-free bread. Cereals having gluten such as wheat must be removed from the diet for the clinical and histological improvement. So, the purpose of this study was to determine the physical, chemical and sensory properties of gluten-free bread produced with barley (T1), corn (T2) and rice (T3) flours instead of wheat flour, using the 1.5 % xanthan gum. The chemical and sensory attributes of bread were evaluated by AOAC method and hedonic test, respectively. Obtained results showed that sample T3 had the highest contents of crude protein (7.94%), ash (2.51%) and carbohydrate (78.31%) as compared to other samples, while fat was lower (2.01%). Regarding moisture, breads prepared with the three different flours were not statistically different at the significance level of p<0.05. However, they differed significantly regarding the specific volume and bake loss. Data also revealed that gluten-free bread, treatment T3 presented the best parameters, being preferred by the sensory evaluation panel, followed by treatment T1 and T2. The overall assessment pointed that the resulting breads treatment T3 was best for all physico-chemical characteristics and, in general, resulted in good sensory behavior, indicating that it could be a promising alternative to wheat flour.

Potential effects of incretin-based therapies on polycystic ovary syndrome in rats: a comparative study of linagliptin versus liraglutide

Low glucagon like peptide1 (GLP-1) level may contribute to the metabolic dysfunction in polycystic ovary syndrome (PCOS). In this study, prospective therapeutic effects of incretin-based drugs; linagliptin versus liraglutide were investigated on letrozole induced PCOS rats. Animals were divided into five groups (control, PCOS, linagliptin, liraglutide and combined). Letrozole was administered for seven weeks (1mg/kg/day,orally). Linagliptin (3mg/kg/day,orally), liraglutide (1.2mg/kg/day,sc) and combined drugs were given for 4 weeks. Measurements of anthropometric, hemodynamics, blood glucose indices, HOMA-IR, serum lipids, TNF-α, NF-kB, and sex hormones were estimated. Antioxidant activities alongside immunohistochemical (PCNA) studies were assessed. The present results proved that both drugs significantly ameliorated most of anthropometric, glycemic, lipid, hormonal, inflammatory and antioxidant indices. Obvious histological improvement was obtained by linagliptin and combined therapy while being questionable by liraglutide . In conclusion, linagliptin caused evident ovarian histological advance rather than liraglutide. Linagliptin may represent a promise in alleviating metabolic, hormonal and unique beneficial histologic effects of PCOS.

An Overview on Primary Sclerosing Cholangitis

Primary sclerosing cholangitis is a progressive liver disease characterized by chronic inflammation leading to liver fibrosis and cirrhosis. Even though the exact pathogenesis is still unclear, a combination of autoimmune, environmental, and ischemic factors could explain certain aspects of the disease. The most important diagnostic step is cholangiography, which can be obtained either by endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiography (MRCP as the gold standard), or percutaneous transhepatic cholangiography. It shows multifocal short biliary duct strictures leading to the “beaded” aspect. Cholangiocarcinoma and colorectal adenocarcinoma are the most feared complications in patients with Primary sclerosing cholangitis (PSC). Continuous screening consists of annual clinical, biochemical, and ultrasound assessments in asymptomatic patients and annual colonoscopy in patients with PSC and inflammatory bowel disease. In newly diagnosed patients with PSC, colonoscopy is mandatory and, if negative, then, a repeat colonoscopy should be performed in 3–5 years. The lack of efficient curative medical treatment makes invasive treatments such as liver transplant and endoscopy the mainstream for managing PSC and its complications. Until now, even though only ursodeoxycholic acid has shown a moderate clinical, biochemical, and even histological improvement, it has no significant influence on the risk of cholangiocarcinoma, liver transplant need, or death risk and it is no longer recommended in treating early PSC. Further studies are in progress to establish the effect of molecular-targeted therapies in PSC.

A234 CLINICAL, ENDOSCOPIC AND HISTOLOGICAL IMPROVEMENT IN COMMON VARIABLE IMMUNODEFICIENCY DISEASE ASSOCIATED ENTEROPATHY WITH VEDOLIZUMAB

Background Common variable immune deficiency (CVID) can be associated with autoimmune manifestations including enteric inflammation and diarrhea. Systemic immunosuppression used in patients with inflammatory bowel disease (IBD) may be associated with increased risk of infection in CVID. Aims We report a patient with CVID associated intestinal enteropathy who underwent clinical, endoscopic and histological improvement after treatment with vedolizumab (IgG1 monoclonal antibody to α4β7 integrin), as well as a concurrent systematic review (SR) of the literature. Methods Case report and systematic literature review. We searched EMBASE, Medline, Cochrane CENTRAL, clinialtrials.gov, and the International Clinical Trials Registry Platform without language restriction using key words to identify patients with CVID associated enteropathy treated with vedolizumab. Clinical, endoscopic and histological outcomes were extracted and safety data. Results A 32-year-old male presented with weight loss, anemia and hypoalbuminemia on a background of chronic diarrhea and recurrent sinus infections. Serology and genetic testing was not consistent with celiac disease. Pan-endoscopy showed complete villous atrophy in the duodenum and biopsies showed and intraepithelial lymphocytosis (IEL) in the duodenum and terminal ileum. CT abdomen showed pan-enteritis with extensive mesenteric lymphadenopathy which were reactive on lymph node excision, as well as bronchiectasis. Pneumococcal vaccination challenge to assess humoral response confirmed CVID. After suboptimal response with steroids and mercaptopurine, treatment was initiated with vedolizumab 300mg IV at weeks 0, 2, and 6, then 8 weekly. This led to normalization of stool frequency, weight gain as well as endoscopic and histological resolution within 6 months of treatment. The SR yielded 101 studies of which 3 case series were identified reporting a total of 7 patients with CVID. In 5 cases there was clinical improvement, 4 reported endoscopic improvement and 3 patients had histologic improvement. No safety concerns associated with vedolizumab were reported. Conclusions Vedolizumab, a selective leucocyte inhibitor to the gut, was able to induce either clinical, endoscopic or histological improvement in 8 published cases in the worldwide literature. Prospective studies are needed to determine whether this treatment could be included in the therapeutic armamentarium for this orphan indication. Funding Agencies None

Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease–associated Intestinal Enteropathy

After treatment with vedolizumab, a patient with diarrhea and malnutrition secondary to common variable immune deficiency (CVID)–related enteropathy was able to achieve clinical, endoscopic, and histological improvement. Vedolizumab may be a treatment option for patients with CVID-associated enteropathy.